The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy
Abstract
:1. Introduction
2. Materials and Methods
2.1. Inclusion Criteria
- -
- The child sought/needed primary or secondary medical care for COVID-19;
- -
- A laboratory (RT-PCR, COVID-19 antigen tests or SARS-CoV-2 antibody testing) confirmed SARS-CoV-2 infection;
- -
- A period of at least 30 days from the diagnosis of the COVID-19 infection;
- -
- The parent’s/caregiver’s/guardian’s consent to participate.
2.2. Outcomes
- -
- To characterize the features of persistent symptoms according to the main circulating variants in Italy at the time of the initial SARS-CoV-2 infection;
- -
- To characterize the behavioral and neurocognitive changes after SARS-CoV-2 infection.
2.3. Exposure and Outcome Variables
2.4. Statistical Analyses
2.5. Ethical Approval
2.6. Patient and Public Involvement
3. Results
3.1. Study Population
3.2. Persistent Symptoms
3.3. Recovery Rates over Time
3.4. Neurocognitive Impact, Mental Health and Behavioral Changes
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Couzin-Frankel, J. Long Covid clues emerge from patient’ blood. Science 2022, 377, 803. [Google Scholar] [CrossRef] [PubMed]
- Subramanian, A.; Nirantharakumar, K.; Hughes, S.; Myles, P.; Williams, T.; Gokhale, K.M.; Taverner, T.; Chandan, J.S.; Brown, K.; Simms-Williams, N.; et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022, 28, 1706–1714. [Google Scholar] [CrossRef] [PubMed]
- Buonsenso, D.; Di Gennaro, L.; De Rose, C.; Morello, R.; D’Ilario, F.; Zampino, G.; Piazza, M.; Boner, A.L.; Iraci, C.; O’Connell, S.; et al. Long-term outcomes of pediatric infections: From traditional infectious diseases to long Covid. Futur. Microbiol. 2022, 17, 551–571. [Google Scholar] [CrossRef] [PubMed]
- Pazukhina, E.; Andreeva, M.; Spiridonova, E.; Bobkova, P.; Shikhaleva, A.; El-Taravi, Y.; Rumyantsev, M.; Gamirova, A.; Bairashevskaia, A.; Petrova, P.; et al. Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: A prospective, cohort study in Moscow (StopCOVID). BMC Med. 2022, 20, 244. [Google Scholar] [CrossRef]
- Buonsenso, D.; Munblit, D.; Pazukhina, E.; Ricchiuto, A.; Sinatti, D.; Zona, M.; De Matteis, A.; D’Ilario, F.; Gentili, C.; Lanni, R.; et al. Post-COVID Condition in Adults and Children Living in the Same Household in Italy: A Prospective Cohort Study Using the ISARIC Global Follow-Up Protocol. Front. Pediatr. 2022, 10, 834875. [Google Scholar] [CrossRef]
- Stephenson, T.; Allin, B.; Nugawela, M.D.; Rojas, N.; Dalrymple, E.; Pereira, S.P.; Soni, M.; Knight, M.; Cheung, E.Y.; Heyman, I.; et al. Long COVID (post-COVID-19 condition) in children: A modified Delphi process. Arch. Dis. Child. 2022, 107, 674–680. [Google Scholar] [CrossRef]
- ISARIC. ISARIC. 2021. Available online: https://isaric.org/research/covid-19-clinical-research-resources/paediatric-follow-up/ (accessed on 1 July 2021).
- Osmanov, I.M.; Spiridonova, E.; Bobkova, P.; Gamirova, A.; Shikhaleva, A.; Andreeva, M.; Blyuss, O.; El-Taravi, Y.; DunnGalvin, A.; Comberiati, P.; et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. Eur. Respir. J. 2021, 59, 2101341. [Google Scholar] [CrossRef]
- Prevalenza e Distribuzione Delle Varianti di SARS-CoV-2 di Interesse Per la Sanità Pubblica in Italia. Available online: https://www.epicentro.iss.it/coronavirus/pdf/sars-cov-2-monitoraggio-varianti-rapporti-periodici-27-maggio-2022.pdf (accessed on 1 August 2022).
- Arostegui, D.; Castro, K.; Schwarz, S.; Vaidy, K.; Rabinowitz, S.; Wallach, T. Persistent SARS-CoV-2 Nucleocapsid Protein Presence in the Intestinal Epithelium of a Pediatric Patient 3 Months After Acute Infection. JPGN Rep. 2021, 3, e152. [Google Scholar] [CrossRef]
- Taweevisit, M.; Chindamporn, A.; Sujjavorakul, K.; Samransamruajkit, R.; Thorner, P.S. Multisystem inflammatory syndrome in children (MIS-C) showing disseminated aspergillosis, cytomegalovirus reactivation and persistent SARS-COV-2: Case report with autopsy review. Pathol.-Res. Pract. 2022, 238, 154106. [Google Scholar] [CrossRef]
- Morello, R.; De Rose, C.; Cardinali, S.; Valentini, P.; Buonsenso, D. Lactoferrin as Possible Treatment for Chronic Gastrointestinal Symptoms in Children with Long COVID: Case Series and Literature Review. Children 2022, 9, 1446. [Google Scholar] [CrossRef]
- Yonker, L.M.; Gilboa, T.; Ogata, A.F.; Senussi, Y.; Lazarovits, R.; Boribong, B.P.; Bartsch, Y.C.; Loiselle, M.; Rivas, M.N.; Porritt, R.A.; et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J. Clin. Investig. 2021, 131, e149663. [Google Scholar] [CrossRef] [PubMed]
- Buonsenso, D.; Di Giuda, D.; Sigfrid, L.; Pizzuto, D.A.; Di Sante, G.; De Rose, C.; Lazzareschi, I.; Sali, M.; Baldi, F.; Chieffo, D.P.R.; et al. Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection. Lancet Child Adolesc. Health 2021, 5, 677–680. [Google Scholar] [CrossRef]
- Cocciolillo, F.; Di Giuda, D.; Morello, R.; De Rose, C.; Valentini, P.; Buonsenso, D. Orbito-Frontal Cortex Hypometabolism in Children with Post-COVID Condition (Long COVID): A Preliminary Experience. Pediatr. Infect. Dis. J. 2022, 41, 663–665. [Google Scholar] [CrossRef] [PubMed]
- Di Gennaro, L.; Valentini, P.; Sorrentino, S.; Ferretti, M.A.; De Candia, E.; Basso, M.; Lancellotti, S.; De Cristofaro, R.; De Rose, C.; Mariani, F.; et al. Extended coagulation profile of children with Long Covid: A prospective study. Sci. Rep. 2022, 12, 18392. [Google Scholar] [CrossRef] [PubMed]
- Ortona, E.; The Long Covid Kids Study Group; Buonsenso, D.; Carfi, A.; Malorni, W. Long COVID: An estrogen-associated autoimmune disease? Cell Death Discov. 2021, 7, 77. [Google Scholar] [CrossRef]
- Buonsenso, D.; Munblit, D.; De Rose, C.; Sinatti, D.; Ricchiuto, A.; Carfi, A.; Valentini, P. Preliminary evidence on long COVID in children. Acta Paediatr. 2021, 110, 2208–2211. [Google Scholar] [CrossRef] [PubMed]
- Buonsenso, D.; Pujol, F.E.; Munblit, D.; Pata, D.; McFarland, S.; Simpson, F.K. Clinical characteristics, activity levels and mental health problems in children with long coronavirus disease: A survey of 510 children. Futur. Microbiol. 2022, 17, 577–588. [Google Scholar] [CrossRef]
- Stephenson, T.; Pereira, S.M.P.; Shafran, R.; de Stavola, B.L.; Rojas, N.; McOwat, K.; Simmons, R.; Zavala, M.; O’Mahoney, L.; Chalder, T.; et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): A national matched cohort study. Lancet Child Adolesc. Health 2022, 6, 230–239, Erratum in Lancet Child Adolesc. Health 2022, 6, e21. [Google Scholar] [CrossRef]
- Radzikowska, U.; Ding, M.; Tan, G.; Zhakparov, D.; Peng, Y.; Wawrzyniak, P.; Wang, M.; Li, S.; Morita, H.; Altunbulakli, C.; et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy 2020, 75, 2829–2845. [Google Scholar] [CrossRef]
- Valentini, P.; Sodero, G.; Buonsenso, D. The Relationship between COVID-19 and Innate Immunity in Children: A Review. Children 2021, 8, 266. [Google Scholar] [CrossRef]
- Brodin, P. SARS-CoV-2 infections in children: Understanding diverse outcomes. Immunity 2022, 55, 201–209. [Google Scholar] [CrossRef] [PubMed]
- Florencio, L.L.; Fernández-De-Las-Peñas, C. Long COVID: Systemic inflammation and obesity as therapeutic targets. Lancet Respir. Med. 2022, 10, 726–727. [Google Scholar] [CrossRef]
- Ritter, A.; Kreis, N.-N.; Louwen, F.; Yuan, J. Obesity and COVID-19: Molecular Mechanisms Linking both Pandemics. Int. J. Mol. Sci. 2020, 21, 5793. [Google Scholar] [CrossRef] [PubMed]
- Du, H.; Dong, X.; Zhang, J.J.; Cao, Y.Y.; Akdis, M.; Huang, P.Q.; Chen, H.W.; Li, Y.; Liu, G.H.; Akdis, C.A.; et al. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. Allergy 2021, 76, 510–532. [Google Scholar] [CrossRef]
- Warner, J.O.; Warner, J.A.; Munblit, D. Hypotheses to explain the associations between asthma and the consequences of COVID-19 infection. Clin. Exp. Allergy 2022, 52, 7–9. [Google Scholar] [CrossRef]
- Buonsenso, D.; Valentini, P.; De Rose, C.; Tredicine, M.; Boza, M.D.C.P.; Camponeschi, C.; Morello, R.; Zampino, G.; Brooks, A.E.S.; Rende, M.; et al. Recovering or Persisting: The Immunopathological Features of SARS-CoV-2 Infection in Children. J. Clin. Med. 2022, 11, 4363. [Google Scholar] [CrossRef]
- Schmidt, S.C.E.; Anedda, B.; Burchartz, A.; Eichsteller, A.; Kolb, S.; Nigg, C.; Niessner, C.; Oriwol, D.; Worth, A.; Woll, A. Physical activity and screen time of children and adolescents before and during the COVID-19 lockdown in Germany: A natural experiment. Sci. Rep. 2020, 10, 21780, Erratum in Sci. Rep. 2021, 11, 24329. [Google Scholar] [CrossRef]
- Loades, M.E.; Chatburn, E.; Higson-Sweeney, N.; Reynolds, S.; Shafran, R.; Brigden, A.; Linney, C.; McManus, M.N.; Borwick, C.; Crawley, E. Rapid Systematic Review: The Impact of Social Isolation and Loneliness on the Mental Health of Children and Adolescents in the Context of COVID-19. J. Am. Acad. Child Adolesc. Psychiatry 2020, 59, 1218–1239.e3. [Google Scholar] [CrossRef]
Characteristic | All Observations | by Period | by Sex | |||||
---|---|---|---|---|---|---|---|---|
N = 679 1 | 1–5 Months, N = 355 1 | 6–9 Months, N = 157 1 | ≥12 Months, N = 154 1 | p-Value 2 | Female, N = 344 3 | Male, N = 330 3 | p-Value 4 | |
age | 10.0 (6.0, 13.0)/676 | 9.0 (5.0, 12.0)/353 | 11.0 (6.0, 13.2)/156 | 11.0 (6.2, 13.8)/154 | 0.003 | 10.0 (6.0, 13.0)/343 | 10.0 (6.0, 13.0)/328 | 0.8 |
Sex | 0.7 | |||||||
female | 344 (51%) | 181 (51%) | 76 (49%) | 81 (54%) | ||||
male | 330 (49%) | 174 (49%) | 79 (51%) | 70 (46%) | ||||
PICU | 4/666 (0.6%) | 0/344 (0%) | 3/157 (1.9%) | 1/152 (0.7%) | 0.031 | 2/338 (0.6%) | 2/323 (0.6%) | >0.9 |
Atopic dermatitis eczema | 52/678 (7.7%) | 31/355 (8.7%) | 8/156 (5.1%) | 13/154 (8.4%) | 0.4 | 24/343 (7.0%) | 28/330 (8.5%) | 0.5 |
Respiratory diseases | 48/678 (7.1%) | 29/355 (8.2%) | 12/156 (7.7%) | 7/154 (4.5%) | 0.3 | 22/343 (6.4%) | 26/330 (7.9%) | 0.5 |
Neurological | 41/678 (6.0%) | 19/355 (5.4%) | 10/156 (6.4%) | 12/154 (7.8%) | 0.6 | 22/343 (6.4%) | 17/330 (5.2%) | 0.5 |
Allergic rhinitis hay fever | 25/676 (3.7%) | 17/354 (4.8%) | 5/155 (3.2%) | 1/154 (0.6%) | 0.062 | 8/341 (2.3%) | 17/330 (5.2%) | 0.055 |
Anxiety | 18/509 (3.5%) | 12/257 (4.7%) | 3/100 (3.0%) | 3/141 (2.1%) | 0.4 | 10/263 (3.8%) | 8/243 (3.3%) | 0.8 |
Food allergy | 23/678 (3.4%) | 13/355 (3.7%) | 5/156 (3.2%) | 5/154 (3.2%) | >0.9 | 11/343 (3.2%) | 12/330 (3.6%) | 0.8 |
Asthma | 21/678 (3.1%) | 12/355 (3.4%) | 3/156 (1.9%) | 6/154 (3.9%) | 0.6 | 8/343 (2.3%) | 13/330 (3.9%) | 0.2 |
Gut problems | 21/678 (3.1%) | 12/355 (3.4%) | 5/156 (3.2%) | 4/154 (2.6%) | >0.9 | 11/343 (3.2%) | 10/330 (3.0%) | 0.9 |
Excessive weight and obesity | 18/678 (2.7%) | 11/355 (3.1%) | 4/156 (2.6%) | 3/154 (1.9%) | 0.9 | 9/343 (2.6%) | 9/330 (2.7%) | >0.9 |
Neurodisability | 16/678 (2.4%) | 10/355 (2.8%) | 1/156 (0.6%) | 4/154 (2.6%) | 0.3 | 8/343 (2.3%) | 8/330 (2.4%) | >0.9 |
Skin problems | 13/667 (1.9%) | 6/351 (1.7%) | 3/156 (1.9%) | 4/147 (2.7%) | 0.7 | 9/339 (2.7%) | 4/323 (1.2%) | 0.2 |
Heart diseases | 10/678 (1.5%) | 6/355 (1.7%) | 2/156 (1.3%) | 2/154 (1.3%) | >0.9 | 5/343 (1.5%) | 5/330 (1.5%) | >0.9 |
Rheumatology | 8/677 (1.2%) | 3/355 (0.8%) | 2/156 (1.3%) | 3/154 (1.9%) | 0.4 | 4/342 (1.2%) | 4/330 (1.2%) | >0.9 |
Hematology | 8/678 (1.2%) | 5/355 (1.4%) | 1/156 (0.6%) | 2/154 (1.3%) | 0.8 | 7/343 (2.0%) | 1/330 (0.3%) | 0.069 |
Immune system diseases | 8/678 (1.2%) | 5/355 (1.4%) | 0/156 (0%) | 3/154 (1.9%) | 0.3 | 5/343 (1.5%) | 3/330 (0.9%) | 0.7 |
Other | 4/656 (0.6%) | 3/346 (0.9%) | 1/152 (0.7%) | 0/146 (0%) | 0.8 | 2/330 (0.6%) | 2/321 (0.6%) | >0.9 |
Genetic conditions | 4/678 (0.6%) | 2/355 (0.6%) | 0/156 (0%) | 2/154 (1.3%) | 0.4 | 3/343 (0.9%) | 1/330 (0.3%) | 0.6 |
Renal Kidney problems | 3/678 (0.4%) | 2/355 (0.6%) | 0/156 (0%) | 1/154 (0.6%) | 0.8 | 0/343 (0%) | 3/330 (0.9%) | 0.12 |
Malnutrition | 1/675 (0.1%) | 1/355 (0.3%) | 0/154 (0%) | 0/154 (0%) | >0.9 | 0/341 (0%) | 1/329 (0.3%) | 0.5 |
Diabetes | 1/677 (0.1%) | 0/355 (0%) | 1/156 (0.6%) | 0/154 (0%) | 0.5 | 0/342 (0%) | 1/330 (0.3%) | 0.5 |
Oncology | 0/678 (0%) | 0/355 (0%) | 0/156 (0%) | 0/154 (0%) | 0/343 (0%) | 0/330 (0%) | ||
Endocrine | 0/676 (0%) | 0/354 (0%) | 0/155 (0%) | 0/154 (0%) | 0/343 (0%) | 0/328 (0%) | ||
Sickle cell disease | 0/287 (0%) | 0/160 (0%) | 0/24 (0%) | 0/92 (0%) | 0/142 (0%) | 0/145 (0%) | ||
Depression | 0/509 (0%) | 0/257 (0%) | 0/100 (0%) | 0/141 (0%) | 0/263 (0%) | 0/243 (0%) | ||
HIV | 0/504 (0%) | 0/254 (0%) | 0/97 (0%) | 0/142 (0%) | 0/262 (0%) | 0/239 (0%) | ||
TB | 0/289 (0%) | 0/159 (0%) | 0/22 (0%) | 0/97 (0%) | 0/142 (0%) | 0/147 (0%) |
Symptom | All Observations | by Period | by Sex | by Age Group | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
N = 679 1 | 1–5 Months, N = 355 1 | 6–9 Months, N = 157 1 | ≥12 Months, N = 154 1 | p-Value 2 | Female, N = 344 1 | Male, N = 330 1 | p-Value 2 | below 10 Years, N = 317 1 | ≥10 Years, N = 359 1 | p-Value 2 | |
Fatigue | 128/679 (19%) | 79/355 (22%) | 23/157 (15%) | 24/154 (16%) | 0.062 | 67/344 (19%) | 60/330 (18%) | 0.7 | 37/317 (12%) | 89/359 (25%) | <0.001 |
Headache | 82/679 (12%) | 49/355 (14%) | 14/157 (8.9%) | 17/154 (11%) | 0.3 | 53/344 (15%) | 29/330 (8.8%) | 0.009 | 17/317 (5.4%) | 65/359 (18%) | <0.001 |
Insomnia | 51/679 (7.5%) | 33/355 (9.3%) | 9/157 (5.7%) | 8/154 (5.2%) | 0.2 | 35/344 (10%) | 16/330 (4.8%) | 0.009 | 12/317 (3.8%) | 39/359 (11%) | <0.001 |
Persistent muscle pain | 47/679 (6.9%) | 36/355 (10%) | 5/157 (3.2%) | 5/154 (3.2%) | 0.002 | 22/344 (6.4%) | 25/330 (7.6%) | 0.5 | 14/317 (4.4%) | 33/359 (9.2%) | 0.015 |
Confusion lack of concentration | 46/678 (6.8%) | 30/355 (8.5%) | 9/157 (5.7%) | 7/153 (4.6%) | 0.2 | 21/343 (6.1%) | 25/330 (7.6%) | 0.5 | 14/317 (4.4%) | 31/358 (8.7%) | 0.027 |
Stomach abdominal pain | 45/678 (6.6%) | 29/355 (8.2%) | 6/157 (3.8%) | 7/154 (4.5%) | 0.10 | 23/344 (6.7%) | 22/329 (6.7%) | >0.9 | 18/317 (5.7%) | 27/358 (7.5%) | 0.3 |
Poor appetite | 43/679 (6.3%) | 22/355 (6.2%) | 14/157 (8.9%) | 7/154 (4.5%) | 0.3 | 19/344 (5.5%) | 24/330 (7.3%) | 0.4 | 19/317 (6.0%) | 24/359 (6.7%) | 0.7 |
Skin rash | 33/678 (4.9%) | 16/355 (4.5%) | 12/156 (7.7%) | 4/154 (2.6%) | 0.10 | 17/344 (4.9%) | 16/329 (4.9%) | >0.9 | 13/316 (4.1%) | 20/359 (5.6%) | 0.4 |
Persistent cough | 31/679 (4.6%) | 20/355 (5.6%) | 5/157 (3.2%) | 5/154 (3.2%) | 0.3 | 8/344 (2.3%) | 23/330 (7.0%) | 0.004 | 21/317 (6.6%) | 10/359 (2.8%) | 0.017 |
Joint pain or swelling | 30/679 (4.4%) | 20/355 (5.6%) | 4/157 (2.5%) | 4/154 (2.6%) | 0.15 | 16/344 (4.7%) | 14/330 (4.2%) | 0.8 | 7/317 (2.2%) | 23/359 (6.4%) | 0.008 |
Diarrhea | 30/679 (4.4%) | 16/355 (4.5%) | 4/157 (2.5%) | 8/154 (5.2%) | 0.5 | 9/344 (2.6%) | 21/330 (6.4%) | 0.018 | 10/317 (3.2%) | 20/359 (5.6%) | 0.13 |
Constipation | 30/679 (4.4%) | 17/355 (4.8%) | 8/157 (5.1%) | 5/154 (3.2%) | 0.7 | 14/344 (4.1%) | 14/330 (4.2%) | >0.9 | 22/317 (6.9%) | 8/359 (2.2%) | 0.003 |
Chest pain | 26/679 (3.8%) | 12/355 (3.4%) | 10/157 (6.4%) | 0/154 (0%) | 0.007 | 14/344 (4.1%) | 12/330 (3.6%) | 0.8 | 5/317 (1.6%) | 21/359 (5.8%) | 0.004 |
Weight loss | 16/436 (3.7%) | 9/213 (4.2%) | 5/141 (3.5%) | 2/77 (2.6%) | >0.9 | 8/223 (3.6%) | 8/208 (3.8%) | 0.9 | 3/175 (1.7%) | 13/261 (5.0%) | 0.075 |
Difficulty breathing chest tightness | 20/679 (2.9%) | 14/355 (3.9%) | 3/157 (1.9%) | 0/154 (0%) | 0.017 | 8/344 (2.3%) | 12/330 (3.6%) | 0.3 | 7/317 (2.2%) | 13/359 (3.6%) | 0.3 |
Feeling nauseous | 19/679 (2.8%) | 14/355 (3.9%) | 3/157 (1.9%) | 1/154 (0.6%) | 0.086 | 10/344 (2.9%) | 9/330 (2.7%) | 0.9 | 3/317 (0.9%) | 16/359 (4.5%) | 0.006 |
Alternated sense of smell | 17/679 (2.5%) | 8/355 (2.3%) | 5/157 (3.2%) | 3/154 (1.9%) | 0.8 | 9/344 (2.6%) | 8/330 (2.4%) | 0.9 | 1/317 (0.3%) | 16/359 (4.5%) | <0.001 |
Alternated taste | 17/679 (2.5%) | 11/355 (3.1%) | 4/157 (2.5%) | 2/154 (1.3%) | 0.6 | 11/344 (3.2%) | 6/330 (1.8%) | 0.3 | 1/317 (0.3%) | 16/359 (4.5%) | <0.001 |
Pain on breathing | 15/604 (2.5%) | 8/326 (2.5%) | 4/151 (2.6%) | 0/116 (0%) | 0.2 | 8/302 (2.6%) | 7/297 (2.4%) | 0.8 | 3/281 (1.1%) | 12/320 (3.8%) | 0.035 |
Hypersomnia | 15/679 (2.2%) | 11/355 (3.1%) | 1/157 (0.6%) | 3/154 (1.9%) | 0.2 | 8/344 (2.3%) | 7/330 (2.1%) | 0.9 | 4/317 (1.3%) | 11/359 (3.1%) | 0.11 |
Loss of smell | 11/679 (1.6%) | 5/355 (1.4%) | 2/157 (1.3%) | 3/154 (1.9%) | 0.8 | 6/344 (1.7%) | 5/330 (1.5%) | 0.8 | 1/317 (0.3%) | 10/359 (2.8%) | 0.011 |
Loss of taste | 11/679 (1.6%) | 7/355 (2.0%) | 1/157 (0.6%) | 3/154 (1.9%) | 0.6 | 5/344 (1.5%) | 6/330 (1.8%) | 0.7 | 3/317 (0.9%) | 8/359 (2.2%) | 0.2 |
Feeling sick vomiting | 8/679 (1.2%) | 5/355 (1.4%) | 1/157 (0.6%) | 1/154 (0.6%) | 0.8 | 3/344 (0.9%) | 5/330 (1.5%) | 0.5 | 4/317 (1.3%) | 4/359 (1.1%) | >0.9 |
Problems speaking or communicating | 3/443 (0.7%) | 2/211 (0.9%) | 0/142 (0%) | 1/87 (1.1%) | 0.4 | 1/230 (0.4%) | 2/208 (1.0%) | 0.6 | 2/174 (1.1%) | 1/268 (0.4%) | 0.6 |
Fainting blackouts | 4/679 (0.6%) | 1/355 (0.3%) | 1/157 (0.6%) | 1/154 (0.6%) | 0.6 | 4/344 (1.2%) | 0/330 (0%) | 0.12 | 1/317 (0.3%) | 3/359 (0.8%) | 0.6 |
Tremor shakiness | 2/490 (0.4%) | 2/257 (0.8%) | 0/139 (0%) | 0/86 (0%) | 0.7 | 1/253 (0.4%) | 1/232 (0.4%) | >0.9 | 1/204 (0.5%) | 1/286 (0.3%) | >0.9 |
Tingling feeling pins and needles | 2/679 (0.3%) | 1/355 (0.3%) | 1/157 (0.6%) | 0/154 (0%) | 0.7 | 2/344 (0.6%) | 0/330 (0%) | 0.5 | 1/317 (0.3%) | 1/359 (0.3%) | >0.9 |
Cannot fully move or control movements | 1/412 (0.2%) | 1/201 (0.5%) | 0/137 (0%) | 0/71 (0%) | >0.9 | 0/217 (0%) | 1/190 (0.5%) | 0.5 | 0/161 (0%) | 1/251 (0.4%) | >0.9 |
Bilateral conjunctivitis | 1/415 (0.2%) | 0/207 (0%) | 1/136 (0.7%) | 0/71 (0%) | 0.5 | 1/217 (0.5%) | 0/193 (0%) | >0.9 | 1/163 (0.6%) | 0/252 (0%) | 0.4 |
Seizures fits | 1/432 (0.2%) | 1/212 (0.5%) | 0/137 (0%) | 0/81 (0%) | >0.9 | 1/225 (0.4%) | 0/202 (0%) | >0.9 | 1/173 (0.6%) | 0/259 (0%) | 0.4 |
Problems with balance | 1/679 (0.1%) | 0/355 (0%) | 0/157 (0%) | 0/154 (0%) | 1/344 (0.3%) | 0/330 (0%) | >0.9 | 0/317 (0%) | 1/359 (0.3%) | >0.9 | |
Dizziness light headedness | 1/679 (0.1%) | 1/355 (0.3%) | 0/157 (0%) | 0/154 (0%) | >0.9 | 0/344 (0%) | 1/330 (0.3%) | 0.5 | 0/317 (0%) | 1/359 (0.3%) | >0.9 |
Double vision blurred vision | 0/679 (0%) | 0/355 (0%) | 0/157 (0%) | 0/154 (0%) | 0/344 (0%) | 0/330 (0%) | 0/317 (0%) | 0/359 (0%) | |||
Problems swallowing or chewing | 0/411 (0%) | 0/196 (0%) | 0/137 (0%) | 0/76 (0%) | 0/212 (0%) | 0/194 (0%) | 0/159 (0%) | 0/252 (0%) | |||
purulent non purulent | 0/148 (0%) | 0/69 (0%) | 0/61 (0%) | 0/17 (0%) | 0/75 (0%) | 0/72 (0%) | 0/61 (0%) | 0/87 (0%) | |||
Lumps or rashes on toes | 0/394 (0%) | 0/196 (0%) | 0/135 (0%) | 0/62 (0%) | 0/206 (0%) | 0/183 (0%) | 0/156 (0%) | 0/238 (0%) |
Characteristic | Omicron, N = 120 1 | Wild Type, N = 201 1 | p-Value 2 |
---|---|---|---|
Fatigue | 16/120 (13%) | 50/201 (25%) | 0.013 |
Headache | 11/120 (9.2%) | 31/201 (15%) | 0.11 |
Insomnia | 6/120 (5.0%) | 27/201 (13%) | 0.016 |
Persistent muscle pain | 4/120 (3.3%) | 27/201 (13%) | 0.003 |
Confusion lack of concentration | 10/120 (8.3%) | 18/201 (9.0%) | 0.8 |
Stomach abdominal pain | 6/120 (5.0%) | 17/201 (8.5%) | 0.2 |
Poor appetite | 4/120 (3.3%) | 17/201 (8.5%) | 0.072 |
Skin rash | 3/120 (2.5%) | 11/201 (5.5%) | 0.2 |
Persistent cough | 11/120 (9.2%) | 6/201 (3.0%) | 0.017 |
Joint pain or swelling | 0/120 (0%) | 17/201 (8.5%) | 0.001 |
Diarrhea | 4/120 (3.3%) | 10/201 (5.0%) | 0.5 |
Constipation | 3/120 (2.5%) | 14/201 (7.0%) | 0.084 |
Chest pain | 2/120 (1.7%) | 9/201 (4.5%) | 0.2 |
Weight loss | 0/10 (0%) | 9/196 (4.6%) | >0.9 |
Difficulty breathing chest tightness | 2/120 (1.7%) | 9/201 (4.5%) | 0.2 |
Feeling nauseous | 3/120 (2.5%) | 10/201 (5.0%) | 0.4 |
Alternated sense of smell | 0/120 (0%) | 6/201 (3.0%) | 0.088 |
Alternated taste | 0/120 (0%) | 8/201 (4.0%) | 0.027 |
Pain on breathing | 0/99 (0%) | 7/200 (3.5%) | 0.10 |
All Observations | by Period | by Sex | by Age Group | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Characteristic | N = 679 1 | 1–5 Months, N = 355 1 | 6–9 Months, N = 157 1 | 12 Months and More, N = 154 1 | p-Value 2 | Female, N = 344 1 | Male, N = 330 1 | p-Value 3 | below 10 Years, N = 317 1 | 10 Years and above, N = 359 1 | p-Value 3 |
Fully recovered | 0.003 | 0.014 | 0.047 | ||||||||
1–4 | 17 (2.6%) | 14 (4.0%) | 2 (1.3%) | 1 (0.7%) | 3 (0.9%) | 14 (4.4%) | 3 (1.0%) | 13 (3.7%) | |||
5–7 | 73 (11%) | 46 (13%) | 7 (4.6%) | 15 (9.9%) | 35 (10%) | 38 (12%) | 31 (9.9%) | 41 (12%) | |||
8–10 | 576 (86%) | 288 (83%) | 144 (94%) | 136 (89%) | 302 (89%) | 269 (84%) | 279 (89%) | 296 (85%) |
fup_Period_1 | fup_Period_2 | Values_1 | Values_2 | p-Value |
---|---|---|---|---|
1–5 | 6–9 | 14/143 | 0/143 | 0.000 |
1–5 | ≥12 m | 14/142 | 7/142 | 0.174 |
6–9 | ≥12 m | 2/121 | 3/121 | 1.000 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Buonsenso, D.; Pazukhina, E.; Gentili, C.; Vetrugno, L.; Morello, R.; Zona, M.; De Matteis, A.; D’Ilario, F.; Lanni, R.; Rongai, T.; et al. The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy. J. Clin. Med. 2022, 11, 6772. https://doi.org/10.3390/jcm11226772
Buonsenso D, Pazukhina E, Gentili C, Vetrugno L, Morello R, Zona M, De Matteis A, D’Ilario F, Lanni R, Rongai T, et al. The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy. Journal of Clinical Medicine. 2022; 11(22):6772. https://doi.org/10.3390/jcm11226772
Chicago/Turabian StyleBuonsenso, Danilo, Ekaterina Pazukhina, Carolina Gentili, Luigi Vetrugno, Rosa Morello, Margherita Zona, Alessia De Matteis, Federico D’Ilario, Roberta Lanni, Teresa Rongai, and et al. 2022. "The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy" Journal of Clinical Medicine 11, no. 22: 6772. https://doi.org/10.3390/jcm11226772